Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
- Conditions
- Non-rhabdomyosarcoma Soft Tissue SarcomaRelapsed/Refractory RhabdomyosarcomaEwing Sarcoma
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03441360
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
🇺🇸Children's Medical Center, Dallas, Texas, United States
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03440424
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03443063
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03433703
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸University of Louisville, Louisville, Kentucky, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
A Study to Evaluate the Food-Effect of H3B-6527
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03424577
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT03386942
- Locations
- 🇯🇵
Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
🇯🇵Eisai Trial Site 10, Koto-Ku, Tokyo, Japan
🇯🇵Eisai Trial Site 5, Matsuyama City, Ehime, Japan
Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03376997
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 278
- Registration Number
- NCT03338296
- Locations
- 🇺🇸
Phoenix Clinical LLC, Phoenix, Arizona, United States
🇺🇸Oviedo Medical Research, LLC, Oviedo, Florida, United States
🇺🇸Long Beach Clinical Trial Services, Inc, Long Beach, California, United States
Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures
- Conditions
- Primary Generalized Tonic-Clonic SeizuresPartial Onset SeizuresSecondarily Generalized Seizures
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT03288129
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸UCSD Epilepsy Center, La Jolla, California, United States
🇺🇸Michigan State University, East Lansing, Michigan, United States
Study of E7386 in Participants With Selected Advanced Neoplasms
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03264664
- Locations
- 🇬🇧
Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇺🇸Mayo Clinic Comprehensive Caner, Rochester, Minnesota, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States